A new device for the injection of tralokinumab is one step closer to approval in European Union member states. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...

BALLERUP, Denmark--(BUSINESS WIRE)--NOT FOR UK USE – NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today presented nine-month interim data from the TRACE study, ...

Results of a trial show that tralokinumab is safe, tolerable and effective in older adults to treat moderate to severe atopic dermatitis. The drug is already approved for adults who have the condition ...

The MarketWatch News Department was not involved in the creation of this content. LEO Pharma Presents Final Results of ECZTEND Long-Term Adbry(R) Trial (tralokinumab-ldrm) in Patients with Moderate-to ...

The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old. Originally ...

Elaine Siegfried, MD, of Saint Louis University School of Medicine discusses the use of biologics to treat atopic dermatitis (AD) and how they differ from other treatments. In this interview clip, ...

No significant differences in the safety or effectiveness of tralokinumab were observed by racial subgroup among patients with AD.

Please provide your email address to receive an email when new articles are posted on . The study included adolescents aged 12 to 17 years and adults. Comorbidities included asthma, food allergy, hay ...

Learn how to administer self-injecting biologic medications with these simple and effective tips. If topical medications haven’t been strong enough to control your psoriasis, your dermatologist may ...

LEO Pharma A/S, a global leader in medical dermatology, today announced the positive results from a 16-week interim analysis of the Phase 3b ADHAND trial evaluating tralokinumab for the treatment of ...